Effective Rifaximin CAS 80621-81-4 EINECS NO 617-130-4

Product Description:

Product Name: Rifaximin CAS NO: 80621-81-4             

Synonyms:

2s-acetyloxy-5,6,21,23-tetrahydroxy-27-m-ethoxy-2,4,11, 16,20,22,24,26-octamethyl-2,7-(epoxypentoeleca(1,11,13)trienimino)benzofuro[4,5-e]pyride[1,2-a]benzimidazole-1,15(2h)-dione;

ole-1,15(2h)-dione,25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-m-ethoxy-2,4,11,16;

Chemical & Physical Properties:

Appearance: Red-orange crystalline powder

Assay :≥99.0%

Density: 1.366 g/cm3

Melting Point: 200-205℃(dec)

Refractive Index: 1.633

Storage Condition: 0-6℃

Solubility: ethanol: soluble1mg/mL

Safety Information:

RTECS: KD1576000

WGK Germany: 2

Toxicity: LD50 orally in rats: >2000 mg/kg (Borelli, Bertoli)

Rifaximin (trade names:RCIFAX, Rifagut, Xifaxan, Zaxine) is a semisynthetic antibiotic based on rifamycin. It has poor oral bioavailability, meaning that very little of the drug will be absorbed into the blood stream when it is taken orally. Rifaximin is used in the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy, for which it received orphan drug status from the U.S. Food and Drug Administration in 1998. It is used in the treatment of traveler's diarrhea and hepatic encephalopathy, for which it received orphan drug status from the U.S. Food and Drug Administration in 1998. Rifaximin interferes with transcription by binding to the β-subunit of bacterial RNA polymerase. This results in the blockage of the translocation step that normally follows the formation of the first phosphodiester bond, which occurs in the transcription process.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.